The effectiveness of tumor necrosis factor-α blocker therapy in patients with axial spondyloarthritis who failed conventional treatment: a comparative study focused on improvement in ASAS Health Index.
Ah-Ra ChoiKi-Jeong ParkJi-Hyoun KangYu Jeong LeeHyun Hee JangMoon-Ju KimTae Jong KimPublished in: Journal of rheumatic diseases (2024)
The research demonstrates that ASAS-HI scores significantly improve with TNF-α blocker therapy in axSpA patients, underscoring ASAS-HI's effectiveness as a tool for evaluating drug responses.
Keyphrases
- randomized controlled trial
- rheumatoid arthritis
- systematic review
- end stage renal disease
- ejection fraction
- newly diagnosed
- public health
- healthcare
- prognostic factors
- emergency department
- ankylosing spondylitis
- mesenchymal stem cells
- health information
- bone marrow
- social media
- combination therapy
- angiotensin ii
- drug induced
- health promotion